MedTrace Logo

Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation

NCT06572930 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-02-24

No results posted yet for this study

Summary

This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.

Conditions

  • Ovarian Stimulation

Interventions

DRUG

Gonal-f (gonadotropin)

Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am.

Sponsors & Collaborators

  • ART Fertility Clinics LLC

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06572930 on ClinicalTrials.gov